Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08OOJ
|
|||
| Former ID |
DIB011312
|
|||
| Drug Name |
CB-5083
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [1], [2], [3] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Company |
Cleave biosciences
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H23N5O2
|
|||
| Canonical SMILES |
CC1=CC2=C(C=CC=C2N1C3=NC4=C(COCC4)C(=N3)NCC5=CC=CC=C5)C(=O)N
|
|||
| InChI |
1S/C24H23N5O2/c1-15-12-18-17(22(25)30)8-5-9-21(18)29(15)24-27-20-10-11-31-14-19(20)23(28-24)26-13-16-6-3-2-4-7-16/h2-9,12H,10-11,13-14H2,1H3,(H2,25,30)(H,26,27,28)
|
|||
| InChIKey |
RDALZZCKQFLGJP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1542705-92-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Valosin-containing protein p97 (VCP) | Target Info | Inhibitor | [4] |
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| Legionellosis | ||||
| Reactome | Hedgehog ligand biogenesis | |||
| Hh mutants that don't undergo autocatalytic processing are degraded by ERAD | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02243917) A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Pharmacological targeting of valosin containing protein (VCP) induces DNA damage and selectively kills canine lymphoma cells. BMC Cancer. 2015; 15: 479. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.